CRVS FY2026 EPS Estimate Lowered by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has lowered its FY2026 earnings estimates for Corvus Pharmaceuticals to ($0.69) per share, down from ($0.62), while the consensus estimate stands at ($0.63).
• Shares of Corvus Pharmaceuticals are currently trading at $4.76, with a market capitalization of $354.30 million and a 52-week range between $2.54 and $10.00.
• Insider trading activity includes Director Peter A. Thompson selling over 1.1 million shares, reducing his position by 14.10%, and highlighting significant activity among hedge funds in the company.

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Analysts at Cantor Fitzgerald cut their FY2026 earnings per share estimates for shares of Corvus Pharmaceuticals in a note issued to investors on Tuesday, August 12th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will post earnings per share of ($0.69) for the year, down from their prior estimate of ($0.62). The consensus estimate for Corvus Pharmaceuticals' current full-year earnings is ($0.63) per share.

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.03.

Other equities analysts have also issued research reports about the stock. Wall Street Zen upgraded shares of Corvus Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. Oppenheimer reaffirmed an "outperform" rating and set a $17.00 price objective (up previously from $15.00) on shares of Corvus Pharmaceuticals in a research report on Friday, May 9th. Finally, Mizuho set a $11.00 price objective on shares of Corvus Pharmaceuticals and gave the company an "outperform" rating in a research report on Tuesday, May 20th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Corvus Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $15.00.

Corvus Pharmaceuticals Stock Performance

NASDAQ CRVS traded up $0.58 during mid-day trading on Thursday, reaching $5.43. 717,062 shares of the stock were exchanged, compared to its average volume of 483,426. The stock has a market capitalization of $404.59 million, a PE ratio of -5.38 and a beta of 0.42. The business's fifty day simple moving average is $4.26 and its 200 day simple moving average is $4.03. Corvus Pharmaceuticals has a 1-year low of $2.54 and a 1-year high of $10.00.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of CRVS. Sowell Financial Services LLC bought a new stake in Corvus Pharmaceuticals during the first quarter worth $38,000. Virtus ETF Advisers LLC bought a new position in shares of Corvus Pharmaceuticals in the fourth quarter valued at about $47,000. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Corvus Pharmaceuticals in the second quarter valued at about $49,000. Sender Co & Partners Inc. bought a new position in shares of Corvus Pharmaceuticals in the second quarter valued at about $52,000. Finally, ProShare Advisors LLC acquired a new position in shares of Corvus Pharmaceuticals in the second quarter valued at about $54,000. Institutional investors and hedge funds own 46.64% of the company's stock.

Insider Transactions at Corvus Pharmaceuticals

In related news, Director Peter A. Thompson sold 1,176,332 shares of Corvus Pharmaceuticals stock in a transaction dated Friday, June 27th. The shares were sold at an average price of $4.16, for a total transaction of $4,893,541.12. Following the completion of the transaction, the director directly owned 7,165,006 shares of the company's stock, valued at $29,806,424.96. This trade represents a 14.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 31.30% of the stock is owned by corporate insiders.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.